• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
158843 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
4 f: u2 @2 a: E* `# ^
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
6 \2 \; E$ u% D9 A8 U: K- c: R
' P7 z+ u0 n" l* I& l: R* q0 c4 W- a+ V+ g. p- W; N! w
Sub-category:/ g0 D' ?8 i$ x
Molecular Targets 1 D1 [7 O, O8 E4 ^1 |
" r$ ~: ?# l+ k# g
6 J- F* e, v4 T9 {
Category:% I# i7 l5 n, `5 }2 d# d" ]
Tumor Biology
* |/ W# y+ P( O) L2 B8 |# d/ ]* L- H9 o

1 C" @# y9 x/ H4 nMeeting:5 X( {; h' Z! X2 W9 ]
2011 ASCO Annual Meeting
+ B. `& ?! {  q6 `; W) c% S
* o- w. y2 O$ A" l" P) Q) |; s$ P$ K2 a4 p* R- |
Session Type and Session Title:
8 L; T6 B) |6 B( XPoster Discussion Session, Tumor Biology
4 j- O, X' ?2 J4 Z  z0 B/ h- G* \) g3 `
" N% N. y% ?- E  c- T, F
Abstract No:
1 \! J) c- a2 Q7 x7 K$ S+ B& ]10517 " Y* G0 [- L* ~

9 X! w: J8 [( Z7 b6 j
* C) l% q7 Y, w: i. W& QCitation:
; a+ p  ?- Y& c0 r, p& @) y" AJ Clin Oncol 29: 2011 (suppl; abstr 10517) ) ^: ~3 Y: F. p7 [1 b
2 R  l$ Q, s( n. y8 s

  Z6 z8 L8 U+ n% {- AAuthor(s):
8 s7 ^1 A, d* d; w3 ZJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
3 {* p: e5 F$ v- K; l3 y, m1 s6 }) G4 |4 B9 X

! \  {& T4 \+ O# I/ ], _' s' Y7 R2 F2 L- z
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* D1 Q( e) K! ~! ^- [- \0 H
5 M' R* M  y" ]9 R9 [$ X  rAbstract Disclosures* G- H/ k) l; K' U1 ~

( r9 w& z4 _" }6 c3 @! d' l1 V- wAbstract:) z! D. Z! J" x0 p. t" L( Z

# ^& O; Y. Q6 F6 p0 g0 q# K/ M4 D0 ?8 @
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 \3 k6 L' T/ }" s
* u% H+ Y! q) C8 ]# f* F9 o2 n 1 k. U- U0 q: t8 S6 X) q! \2 W8 A" @
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 - W/ G/ u, B' m/ y- n7 w
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

2 |( N* r1 X' N, T0 d! U# m化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
" v( _4 b; k" @; K% d9 \! \( K# [易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。/ F) U+ J, e  R$ c5 {
ALK一个指标医院要900多 ...
( I& Q9 P5 x* `; I7 |; l1 Z' y4 Y: I
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?8 V  t0 L7 k2 n/ S/ z% S" _+ g
2 s& C% R1 H$ z! v+ g0 B
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表